

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

PROFIT ALERT

This announcement is made by Tianda Pharmaceuticals Limited (the “Company”) and its subsidiaries (the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Board of Directors of the Company (the “Board”) hereby informs the shareholders of the Company and potential investors that based on preliminary assessment of the Group’s latest unaudited consolidated management accounts and the information currently available, the Group is expected to record consolidated loss for the financial year ended 31 March 2015 (the “Current Financial Year”) as compared with the consolidated profit recorded in the financial year ended 31 March 2014. Due to Yunnan Meng Sheng Pharmaceutical Co., Limited, a subsidiary of the Company, took longer time than expected for its construction works for expansion of the original production line and the New GMP authentication that the New GMP Version certificate was obtained in late January 2015. As a consequence, its sales and earnings were affected and in turn led to the expected Group’s consolidated loss.

This announcement is a preliminary estimate by the Board according to the Group’s latest unaudited consolidated management accounts and the information currently available, which is not based on any information which has been audited or reviewed by the independent auditor of the Company. Further details of financial result and performance of the Group will be disclosed when the Group’s results for the Current Financial Year are published.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman

Hong Kong, 24 April 2015

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (the Chairman and Managing Director), Mr. LIU Huijiang, Mr. LUI Man Sang and Mr. SHI Shaobin and the independent non-executive Directors are Mr. CHIU Sung Hong, Mr. CHIU Fan Wa and Mr. LAM Yat Fai.